Indication

In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).

Medicine details

Medicine name:
apalutamide (Erleada)
SMC ID:
SMC2472
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
12 September 2022
SMC meeting date:
TBC
Patient group submission deadline:
04 July 2022